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Background
Despite significant advances in genomics, proteomics and
metabolomics, the identification and validation of circu-
latory immunological biomarkers in cancer patients,
which could be useful to monitor disease progression
and response to immunotherapeutic treatments, remains
as elusive as ever. Circulatory biomarkers, being easily
accessible, may provide crucial guidance and be incorpo-
rated in routine point of care practices. Immunological
biomarkers could aid clinical decision making regarding
initiation, cessation, boost or change of treatment and
assessment of therapeutic responses. In light of the
increasing number of immunotherapeutic options, this is
an area receiving renewed attention.
Methods
We have investigated two different approaches to identify
circulating immunological mediators in clinical samples.
We have measured immunological mediators by ELISA or
Multiplex assays in either the sera or in the supernatants
of TruCulture® samples from patients with pancreatic
(NCT01303172) and colorectal cancer (NCT01539824)
recruited to clinical trials investigating the use of
IMM-101, an immunotherapeutic agent. IMM-101, a sus-
pension of heat-killed whole cell Mycobacterium obuense
(NCTC13365) for intra-dermal injection, is a systemic
immunomodulator which has effects on innate and adap-
tive immune responses and which may have application
across a variety of tumor types. The TruCulture® system
assesses immune cell activity within a single self-contained
sterile tube containing immunological stimulants, such as
SEB and anti-CD28, and requiring an incubation step of
24hrs in a dry-heat block.
Results
Nursing staff reported that the tubes were simple to
manage, the protocol easy to perform at point of care
and sample acquisition was well integrated within the
clinical trial protocol. Supernatants were stored until
ready for analysis. Data revealed that this technique
offers a way of reliably measuring immunological
responses by patients before and after treatment. Com-
pared to multiplex analysis of sera samples, which
detected only low levels of a very limited range of cyto-
kines, data show that this system allows for detection of
a full range of cytokines (e.g. IFN-g, IL-2, IL-4, IL-7)
and that it is a promising technique to monitor patients’
immunological responses. Sera analysis by ELISA and
Multiplex assay did reveal the presence of only low mea-
surable levels of cytokines, while levels of chemokines
(e.g. MCP-1, MIP-1a and MIP-1b) were consistently
detected. We are currently analysing samples for inflam-
matory mediators.
Conclusions
Preliminary data indicate that novel inflammatory mar-
kers such as Apolipoprotein E, may be used to monitor
treatment response. It is likely, however, that patterns of
markers may prove potentially more useful than indivi-
dual markers.
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